Companies Cryptocurrencies
Oncolytics Biotech Inc
Oncolytics Biotech Inc
Exchange: NasdaqGS
IPO Date: 01/06/2000
CEO: Dr. Matthew Coffey
Biotechnology Healthcare 🔗
  • ONCY
  • 1.13
  • 66081268
    market cap
  • -0.01999998
If you bought

shares of Oncolytics Biotech Inc (ONCY) on
You would have made
Old Price $12 Current Price $12

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 30 full-time employees. The firm is focused on the development of REOLYSIN, its cancer therapeutic. The firm’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The firm focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The firm has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The firm is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Address: 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7 Calgary ALBERTA T2N 1X7

Stay updated.